LONDON (Alliance News) - Sareum Holdings PLC said Friday that Sierra Oncology Inc reported preclinical efficacy data for an immunotherapy combination with its SRA737 inhibitor in lung cancer.
Sareum licences the product to Sierra Oncology.
Chief Executive Officer Tim Mitchell said: "We are encouraged by the findings of this study, which was presented at the American Association for Cancer Research conference.
"It showed SRA737 activated the innate immune signalling stimulator of interferon genes pathway and demonstrated clear anti-tumour activity in an immunocompetent preclinical model of small cell lung cancer."
The company added that the "encouraging preclinical results" highlighted additional potential for SRA737 warranting further evaluation.
Sareum shares were trading up 5.7% at 0.74 pence each.
Sareum (SAR)